Dobesilate Repurposing for AMD Retinal Architecture Normalization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for age-related macular degeneration, particularly wet AMD, are associated with side effects like inflammation and fibrosis, and are expensive, while dry AMD lacks effective treatments, necessitating a safer, less expensive, and more efficient therapeutic option.
Innovation Solution
The use of dobesilate and its pharmaceutically acceptable salts, such as diethylamine 2,5-dihydroxybenzenesulfonate, for treating both wet and dry forms of age-related macular degeneration, which normalizes retinal architecture and improves visual acuity through intravitreal or topical administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current treatments for wet AMD are used, then visual acuity can be maintained or improved, but side effects such as inflammation and fibrosis occur and treatment cost increases
Solution Approach 1:
The patent employs dobesilate, a short-acting vasoprotective agent with a brief half-life, administered repeatedly at intervals. This approach replaces chronic, expensive anti-VEGF therapies with a cost-effective, short-acting alternative that achieves therapeutic goals without the severe side effects of current treatments.
Solution Approach 2:
The invention changes the therapeutic parameter from anti-VEGF mechanism to vasoprotective mechanism using dobesilate. This parameter change shifts the treatment approach from blocking vascular growth to protecting existing vessels, thereby improving visual acuity while avoiding inflammation and fibrosis associated with current therapies.
2Measurement precision
If current treatments for wet AMD are used, then visual acuity can be maintained or improved, but treatment cost increases significantly
Solution Approach 1:
The patent employs dobesilate, a short-acting vasoprotective agent with a brief half-life, administered repeatedly at intervals. This approach replaces chronic, expensive anti-VEGF therapies with a cost-effective, short-acting alternative that achieves therapeutic goals without the severe side effects of current treatments.
Solution Approach 2:
The invention uses dobesilate, a well-established, inexpensive drug originally developed for other indications, and repurposes it for AMD treatment. This copying approach leverages an existing safe and cheap medication to address a costly medical problem, avoiding the need for expensive new drug development.
3Object-affected harmful factors
If no treatment is used for dry AMD, then no side effects occur, but visual acuity deteriorates due to geographic atrophy
Solution Approach 1:
The patent applies dobesilate to enhance the eye's own protective mechanisms against geographic atrophy. The drug stimulates endogenous vasoprotective pathways and promotes survival of retinal vessels and surrounding tissue, enabling the ocular system to fight atrophy through its own reinforced defenses rather than external intervention.
Solution Approach 2:
The invention administers dobesilate prophylactically to prevent geographic atrophy progression before significant vision loss occurs. By treating early-stage dry AMD with vasoprotective therapy, the drug preserves retinal architecture and visual acuity before irreversible damage sets in, acting as a preventive measure rather than a corrective one.
Data Source
AI summary
The invention relates to the safety and efficacy of Dobesilate, a very well known pharmaceutical composition, used as intravitreal injection in patients with age-related macular degeneration.